GEN-MKT-18-7897-A
Aug 22, 2017 | Blogs, Technology | 0 comments
Scientists and analysts across all fields of testing and research are increasingly challenged by complex samples requiring advanced analytical selectivity. And where LC-MS/MS sensitivity alone is not enough to meet the demands of modern day quantitative performance, Differential Ion Mobility Spectrometry (DMS) has proven to be a valuable addition.
Break Through the Selectivity Barrier of Your LC/MS-MS SeparationsSCIEX offers the most innovative solution with its SelexION® DMS Technology. It is a small, planar mobility cell that is easy to install (in less than 2 minutes), easy-to-use and can significantly increase analytical separation power. No other ion mobility separation tool offers the reproducibility, robustness, and simplicity to deliver highly selective and sensitive quantitative and qualitative analyses, within a UHPLC time scale.
How does SelexION make this possible?The SelexION DMS technology separates ions based on differences in mobility in two different regions of the field dependent mobility curve. Due to its small size, the system can operate with very short ion residence times with optimal performance when using chemical modifiers. The DMS device can also be used in ‘transparent mode’ to allow for maximal workflow flexibility.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network